The above chart shows Gilead Sciences's revenue percentage share by segment (products and services).
In fiscal year 2023, Gilead Sciences's revenue by segment is as follows:
- Cell Therapy Products, Total Cell Therapy Product Sales generated $2.24 B in revenue, representing 8.75% of its total revenue.
- Hepatitis B Virus / Hepatitis Delta Virus Product generated $1.02 B in revenue, representing 3.97% of its total revenue.
- Other Products, Total Other product sales generated $859.00 M in revenue, representing 3.36% of its total revenue.
- Products, Other HIV generated $18.23 B in revenue, representing 71.23% of its total revenue.
- Trodelvy generated $1.06 B in revenue, representing 4.15% of its total revenue.
- Veklury generated $2.18 B in revenue, representing 8.53% of its total revenue.
The
biggest segment for Gilead Sciences is the Products, Other HIV, which represents 71.23% of its total revenue.
The
smallest segment for Gilead Sciences is the Other Products, Total Other product sales, which represents 3.36% of its total revenue.
The above chart shows Gilead Sciences's revenue percentage share by segment (products and services).
In fiscal year 2024, Gilead Sciences's revenue by segment is as follows:
- Cell Therapy Products, Total Cell Therapy Product Sales generated $2.38 B in revenue, representing 9.14% of its total revenue.
- Other Products, Total Other product sales generated $889.00 M in revenue, representing 3.42% of its total revenue.
- Products, Other HIV generated $19.61 B in revenue, representing 75.46% of its total revenue.
- Trodelvy generated $1.32 B in revenue, representing 5.06% of its total revenue.
- Veklury generated $1.80 B in revenue, representing 6.92% of its total revenue.
The
biggest segment for Gilead Sciences is the Products, Other HIV, which represents 75.46% of its total revenue.
The
smallest segment for Gilead Sciences is the Other Products, Total Other product sales, which represents 3.42% of its total revenue.
The above chart shows Gilead Sciences's revenue percentage share by segment (products and services).
In fiscal year 2025, Gilead Sciences's revenue by segment is as follows:
- AmBisome generated $509.00 M in revenue, representing 0.96% of its total revenue.
- Biktarvy generated $14.33 B in revenue, representing 26.96% of its total revenue.
- Cell Therapy Products, Total Cell Therapy Product Sales generated $2.18 B in revenue, representing 4.11% of its total revenue.
- Descovy generated $2.76 B in revenue, representing 5.19% of its total revenue.
- Genvoya generated $1.50 B in revenue, representing 2.82% of its total revenue.
- Odefsey generated $1.17 B in revenue, representing 2.19% of its total revenue.
- Other generated $290.00 M in revenue, representing 0.55% of its total revenue.
- Other HIV generated $500.00 M in revenue, representing 0.94% of its total revenue.
- Other Liver Disease generated $874.00 M in revenue, representing 1.64% of its total revenue.
- Other Products, Total Other product sales generated $799.00 M in revenue, representing 1.5% of its total revenue.
- Products, Other HIV generated $20.75 B in revenue, representing 39.03% of its total revenue.
- Royalty, contract and other revenues generated $527.00 M in revenue, representing 0.99% of its total revenue.
- Sofosbuvir/Velpatasvir generated $1.27 B in revenue, representing 2.39% of its total revenue.
- Symtuza - Revenue share generated $495.00 M in revenue, representing 0.93% of its total revenue.
- Tecartus generated $344.00 M in revenue, representing 0.65% of its total revenue.
- Trodelvy generated $1.40 B in revenue, representing 2.63% of its total revenue.
- Veklury generated $911.00 M in revenue, representing 1.71% of its total revenue.
- Vemlidy generated $1.07 B in revenue, representing 2.01% of its total revenue.
- Yescarta generated $1.50 B in revenue, representing 2.81% of its total revenue.
The
biggest segment for Gilead Sciences is the Products, Other HIV, which represents 39.03% of its total revenue.
The
smallest segment for Gilead Sciences is the Other, which represents 0.55% of its total revenue.
Submit Feedback
